These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26943962)

  • 1. Immunomodulation by vitamin D in multiple sclerosis: More than IL-17.
    Smolders J; Muris AH; Damoiseaux J
    J Neuroimmunol; 2016 Mar; 292():79-80. PubMed ID: 26943962
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
    Toghianifar N; Ashtari F; Zarkesh-Esfahani SH; Mansourian M
    J Neuroimmunol; 2015 Aug; 285():125-8. PubMed ID: 26198928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The elusive biomarker for personalized medicine in multiple sclerosis: the search continues.
    Rudick RA
    Neurology; 2012 Aug; 79(6):498-9. PubMed ID: 22573625
    [No Abstract]   [Full Text] [Related]  

  • 4. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.
    Røsjø E; Steffensen LH; Jørgensen L; Lindstrøm JC; Šaltytė Benth J; Michelsen AE; Aukrust P; Ueland T; Kampman MT; Torkildsen Ø; Holmøy T
    J Neurol; 2015 Dec; 262(12):2713-21. PubMed ID: 26429571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
    Bălaşa R; Bajko Z; Huţanu A
    Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.
    Holmøy T; Lindstrøm JC; Eriksen EF; Steffensen LH; Kampman MT
    BMC Neurol; 2017 Apr; 17(1):67. PubMed ID: 28376767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
    Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
    CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune regulatory effects of high dose vitamin D
    Muris AH; Smolders J; Rolf L; Thewissen M; Hupperts R; Damoiseaux J;
    J Neuroimmunol; 2016 Nov; 300():47-56. PubMed ID: 27806875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of VDR mRNA but not NF-κB surprisingly decreased after vitamin D treatment in multiple sclerosis patients.
    Shirvani-Farsani Z; Kakhki MP; Gargari BN; Doosti R; Moghadasi AN; Azimi AR; Behmanesh M
    Neurosci Lett; 2017 Jul; 653():258-263. PubMed ID: 28576565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients.
    Kalinowska-Łyszczarz A; Szczuciński A; Pawlak MA; Losy J
    J Neurol Sci; 2011 Jan; 300(1-2):81-5. PubMed ID: 20947098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.
    Smolders J; Hupperts R; Barkhof F; Grimaldi LM; Holmoy T; Killestein J; Rieckmann P; Schluep M; Vieth R; Hostalek U; Ghazi-Visser L; Beelke M;
    J Neurol Sci; 2011 Dec; 311(1-2):44-9. PubMed ID: 21620416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D-mediated immune regulation in multiple sclerosis.
    Correale J; Ysrraelit MC; Gaitán MI
    J Neurol Sci; 2011 Dec; 311(1-2):23-31. PubMed ID: 21723567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D in MS: a vitamin for 4 seasons.
    Ascherio A; Marrie RA
    Neurology; 2012 Jul; 79(3):208-10. PubMed ID: 22700805
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfavorable outcomes during treatment of multiple sclerosis with high doses of vitamin D.
    Fragoso YD; Adoni T; Damasceno A; de Albuquerque Damasceno CA; Ferreira ML; Finkelzstejn A; Gomes S; Goncalves MV; Grzesiuk AK; Lins S; Mendes MF; de Oliveira FT; Parolin MF; Rocha CF; Tauil CB
    J Neurol Sci; 2014 Nov; 346(1-2):341-2. PubMed ID: 25183235
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of high-dose vitamin D
    Røsjø E; Lossius A; Abdelmagid N; Lindstrøm JC; Kampman MT; Jørgensen L; Sundström P; Olsson T; Steffensen LH; Torkildsen Ø; Holmøy T
    Mult Scler; 2017 Mar; 23(3):395-402. PubMed ID: 27325604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
    Simpson S; Stewart N; van der Mei I; Otahal P; Charlesworth J; Ponsonby AL; Blizzard L; Dwyer T; Pittas F; Gies P; Taylor B
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):200-7. PubMed ID: 24790215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17A Levels Vary in Relapsing-Remitting Multiple Sclerosis Patients in Association with Their Age, Treatment and the Time of Evolution of the Disease.
    Guerrero-García Jde J; Castañeda-Moreno VA; Torres-Carrillo N; Muñoz-Valle JF; Bitzer-Quintero OK; Ponce-Regalado MD; Mireles-Ramírez MA; Valle Y; Ortuño-Sahagún D
    Neuroimmunomodulation; 2016; 23(1):8-17. PubMed ID: 26599431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
    Røsjø E; Myhr KM; Løken-Amsrud KI; Bakke SJ; Beiske AG; Bjerve KS; Hovdal H; Lilleås F; Midgard R; Pedersen T; Šaltytė Benth J; Torkildsen Ø; Wergeland S; Michelsen AE; Aukrust P; Ueland T; Holmøy T
    J Neuroimmunol; 2015 Mar; 280():21-8. PubMed ID: 25773151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.